BD (Becton, Dickinson and Company), a global leader in medical technology, has announced a $110 million investment to expand its production of prefillable syringes in the United States, a move aimed at accelerating biologic and GLP-1 drug delivery while strengthening domestic pharmaceutical manufacturing. The investment will establish production of the BD Neopak™ Glass Prefillable Syringe platform at the company’s Columbus, Nebraska facility, creating approximately 120 new jobs and reinforcing supply chain resilience within BD’s Pharmaceutical Systems portfolio.
The expansion has been welcomed by state leaders, including U.S. Senator Pete Ricketts, who highlighted the economic and strategic importance of the project. “This is good news for Nebraska,” Ricketts said, noting that the investment could bring more than 100 new jobs to the state and further demonstrate BD’s commitment to keeping critical manufacturing operations in the U.S. He also emphasized the company’s long-standing partnership with Nebraska.
BD Neopak™ Glass Prefillable Syringes are designed to address the increasingly complex requirements of biologics and combination products. Available in 1 mL and 2.25 mL formats, the platform supports high-viscosity formulations, drug-container compatibility, and seamless integration with drug delivery devices. The syringes are specifically engineered for use with autoinjectors, enabling patient-centric administration in both clinical and at-home settings.
According to Patrick Jeukenne, worldwide president of BD Pharmaceutical Systems, rising demand for biologics and GLP-1 therapies is driving the company to expand its American manufacturing footprint. He said the Nebraska investment aligns with BD’s long-term growth strategy and its commitment to partnering with biopharmaceutical companies developing next-generation therapies that require advanced drug delivery solutions.
Of the total investment, $100 million will be used to establish BD Neopak™ Glass Prefillable Syringe production at the Columbus site, with initial supply expected in mid-2026. An additional $10 million will enhance cannula manufacturing capabilities, alongside other line upgrades and capacity improvements to meet growing global demand. Together, these initiatives will add about 120 new positions at the facility.
The announcement builds on BD’s recent $35 million investment to expand prefilled flush syringe manufacturing in Columbus, which is expected to add another 50 jobs. With more than 75 years of manufacturing history in the region, the Columbus site plays a strategic role in BD’s global network. The company has also committed to investing more than $2.5 billion in U.S. manufacturing over the next five years, underscoring its focus on strengthening domestic supply chains and ensuring reliable access to life-saving injectable therapies.